The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

Aging is a gradual and irreversible pathophysiological process. It presents with declines in
tissue and cell functions and significant increases in the risks of various aging-related …

Abstract Aim The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management
of Patients With Chronic Coronary Disease” provides an update to and consolidates new …

Background SGLT2 inhibitors are strongly recommended in guidelines to treat patients with
heart failure with reduced ejection fraction, but their clinical benefits at higher ejection …

Whether the sodium–glucose cotransporter 2 inhibitor dapagliflozin reduces the risk of a
range of morbidity and mortality outcomes in patients with heart failure regardless of ejection …

Importance Heart failure with preserved ejection fraction (HFpEF), defined as HF with an EF
of 50% or higher at diagnosis, affects approximately 3 million people in the US and up to 32 …

Objective The objective of this clinical practice guideline is to provide updated and new
evidence-based recommendations for the comprehensive care of persons with diabetes …

The incidence and prevalence of heart failure with preserved ejection fraction (HFpEF)
continue to rise in tandem with the increasing age and burdens of obesity, sedentariness …

The American College of Cardiology (ACC) has a long history of developing documents (eg,
decision pathways, health policy statements, appropriate use criteria) to provide members …

Large traditional clinical trials suggest that sodium-glucose co-transporter 2 inhibitors
improve symptoms in patients with heart failure and reduced ejection fraction (HFrEF) and in …